Browse News
Filter News
Found 72 articles
-
Olink said the measurement of proteins at "population scale" provides the ability to improve the understanding of underlying mechanisms of diseases.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
4/12/2022
Recce Pharmaceuticals Limited is pleased to announce the Intellectual Property Department of the Hong Kong Special Administrative Region has granted patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection,” furthering marketing and manufacturing exclusivity to February 2037.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
3/30/2022
Recce Pharmaceuticals Ltd is pleased to report Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) cohort four at 1,000mg (twenty-fold increase on cohort one 50mg dose), indicating a good safety and tolerability profile among 10 healthy male subjects.
-
Recce Pharmaceuticals Receives Research and Development (R&D) Incentive Rebate
3/29/2022
Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, is pleased to announce it has received a Research and Development Tax Incentive rebate of A$3,084,955.19 from the Australian Tax Office for the year ending June 30, 2021.
-
Recce Pharmaceuticals Announces Safety Committee Clears Next Dose in Phase I Study of RECCE® 327
3/8/2022
Recce Pharmaceuticals Ltd is pleased to report an Independent Safety Committee data review of 10 healthy human subjects intravenously dosed in the Phase I intravenous clinical trial of RECCE® 327, demonstrating a good safety and tolerability profile – unanimously recommending cohort four to commence.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Recce Pharmaceuticals Announces Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
2/8/2022
Recce Pharmaceuticals Ltd is pleased to report Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) cohort three at 500mg (tenfold increase on cohort one 50mg dose), indicating a good safety and tolerability profile among seven healthy male subjects.
-
Recce Pharmaceuticals Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
1/19/2022
Recce Pharmaceuticals Ltd is pleased to report further positive data from its Phase I intravenous (IV) clinical trial of RECCE® 327 (R327).
-
A Perfect Storm of Superbugs
1/17/2022
To alleviate the problem of antibiotic-resistant bacteria, or superbugs, several biotechnology companies are developing different strategies to target and kill these microorganisms. -
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look.